David Heimbrook

6.5k citations

69 papers · 4.6k indexed · 2 hit papers · h-index 34

Impact in

Oncology top 1%
- Cancer-related Molecular Pathways
Molecular Biology top 2%
- Ubiquitin and proteasome pathways
- Melanoma and MAPK Pathways
- Epigenetics and DNA Methylation
- DNA Repair Mechanisms

Papers in

Oncology 35
- Cancer-related Molecular Pathways 19
Biophysics 4

Co-authors: Christian Tovar Lyubomir T. Vassilev Allen Oliff Kathryn Packman Xiaolan Zhao Kenneth Kolinsky Stephen G. Sligar Brian Higgins
Journals: Journal of Biological Chemistry (10 papers)Molecular and Cellular Biology (8 papers)Cancer Research (7 papers)Proceedings of the National Academy of Sciences (4 papers)Molecular Cancer Therapeutics (4 papers)
Partner nations: United States Switzerland Canada

In The Last Decade

David Heimbrook

69 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1 2006 · 620 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2006 Proceedings of the National Academy of Sciences
2006 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by David Heimbrook

Since Specialization

Citations

This map shows the geographic impact of David Heimbrook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Heimbrook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Heimbrook more than expected).

Fields of papers citing papers by David Heimbrook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Heimbrook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Heimbrook. The network helps show where David Heimbrook may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David Heimbrook, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Heimbrook Line = papers co-authored together David Heimbrook links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical Optimization of MDM2 Antagonist Scheduling for Cancer Treatment by Using a Model-Based Approach Clinical Cancer Research ·Brian Higgins, Kelli Glenn, Antje‐Christine Walz, Christian Tovar, Zoran Filipovic, K. Vogel, Jesse Drapekin, Kenneth Kolinsky, 啓輔上原, Behrooz Shafiei, Rosario Garrido, Michael Linn, Christophe Meille, David Heimbrook, Lyubomir T. Vassilev, Kathryn Packman	2014	50
2	Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-Raf V600E Mutation Cancer Research ·Huisheng Wang, Sherif Daouti, Wenhui Li, Wen Yang, Elber Gomes Souza, Brian Higgins, Kathryn Packman, Neal Rosen, John F. Boylan, David Heimbrook, Huifeng Niu	2011	62
3	Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, William D. Bradley, Richard J. Lee, Kathleen Schostack, Mary Ellen Simcox, Scott Kopetz, David Heimbrook, Brian Lestini, Gideon Bollag, Fei Su	2011	170
4	Preclinical In vivo Evaluation of Efficacy, Pharmacokinetics, and Pharmacodynamics of a Novel MEK1/2 Kinase Inhibitor RO5068760 in Multiple Tumor Models Molecular Cancer Therapeutics ·Sherif Daouti, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Huisheng Wang, Elber Gomes Souza, John Moliterni, Nicholas Huby, Nader Fotouhi, Taija Häätylä, Petra Goelzer, Harpreet Sandhu, Jiakui Li, Aruna Railkar, David Heimbrook, Huifeng Niu	2010	23
5	RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models Cancer Research ·Hong Yang, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Zenaida Go, Raman Iyer, Stanley P. Kolis, Sylvia Zhao, W. Jaskółowski, Joseph F. Grippo, Kathleen Schostack, Mary Ellen Simcox, David Heimbrook, Gideon Bollag, Fei Su	2010	307
6	Characterization of a Novel Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor with a Unique Mechanism of Action for Cancer Therapy Cancer Research ·Sherif Daouti, Huisheng Wang, Wenhui Li, Brian Higgins, Kenneth Kolinsky, Kathryn Packman, Rafael Soares de Souza Pitombeira, Norman Kong, Nicholas Huby, Wen Yang, Qing Xiang, Frank Podlaski, Yang He, Nader Fotouhi, David Heimbrook, Huifeng Niu	2009	25
7	Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties Cancer Research ·Leopoldo Luistro, Wei He, Melissa Smith, Kathryn Packman, Maria Vilenchik, Daisy Carvajal, John G. Roberts, James J. Cai, Windy Berkofsky‐Fessler, Holly Hilton, Michael Linn, Alexander Flohr, Taís Economides Gallina, Helmut Jacobsen, Kelli Glenn, David Heimbrook, John F. Boylan	2009	154
8	Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation Cell Cycle ·Mingxuan Xia, Dejan Knezevic, Christian Tovar, Baoying Huang, David Heimbrook, Lyubomir T. Vassilev	2008	62
9	Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents Molecular Cancer Therapeutics ·Fei Su, Hong Yang, J. C. Conner, Jianping Chen, Kenneth Kolinsky, Kathryn Packman, David Heimbrook	2007	3
10	Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy Proceedings of the National Academy of Sciences ·Christian Tovar, James Rosinski, Zoran Filipovic, Brian Higgins, Kenneth Kolinsky, Holly Hilton, Xiaolan Zhao, Binh Thanh Vu, Weiguo Qing, Kathryn Packman, Ola Myklebost, David Heimbrook, Lyubomir T. Vassilev Hit paper breakdown →	2006	553
11	Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1 Proceedings of the National Academy of Sciences ·Lyubomir T. Vassilev, Christian Tovar, Shaoqing Chen, Dejan Knezevic, Xiaolan Zhao, Hongmao Sun, David Heimbrook, Li Chen Hit paper breakdown →	2006	620
12	Phosphorylation of p53 on Key Serines Is Dispensable for Transcriptional Activation and Apoptosis Journal of Biological Chemistry ·Thelma Thompson, Christian Tovar, Hong Yang, Daisy Carvajal, Binh Thanh Vu, Qunli Xu, Geoffrey M. Wahl, David Heimbrook, Lyubomir T. Vassilev	2004	198
13	Anions Modulate the Potency of Geranylgeranyl-Protein Transferase I Inhibitors Journal of Biological Chemistry ·Hans E. Huber, R. Robinson, Sanika M Thakur, Deborah D. Nahas, Marc Abrams, Carolyn A. Buser, Robert B. Lobell, D Patrick, Neville J. Anthony, Christopher J. Dinsmore, Samuel Graham, George D. Hartman, William C. Lumma, Theresa M. Williams, David Heimbrook	2001	16
14	Oncogene products as therapeutic targets for cancer Current Opinion in Oncology ·Pearl S. Huang, David Heimbrook	1997	16
15	Cloning and mutagenesis of the p110α subunit of human phosphoinositide 3′-hydroxykinase Bioorganic & Medicinal Chemistry ·Steven M. Stirdivant, А. В. Локтєв, Robert R. Conroy, Stanley F. Barnett, DE FARIAS FAGUNDES ALINE GONÇALVES, Allen Oliff, David Heimbrook	1997	4
16	Interfacial Catalysis by Phosphoinositide 3'-Hydroxykinase Biochemistry ·Stanley F. Barnett, DE FARIAS FAGUNDES ALINE GONÇALVES, Steven M. Stirdivant, А. В. Локтєв, Robert R. Conroy, David Heimbrook	1995	13
17	Human Papillomavirus Type 16 E7 Protein Inhibits DNA Binding by the Retinoblastoma Gene Product Molecular and Cellular Biology ·Steven M. Stirdivant, Hans E. Huber, Denis R. Patrick, Deborah Defeo-Jones, Venkata Harish, Victor M. Garsky, Allen Oliff, David Heimbrook	1992	2
18	Activity of a recombinant transforming growth factor-α-Pseudomonas exotoxin hybrid protein against primary human tumor colony-forming units Investigational New Drugs ·Daniel D. Von Hoff, Martha H. Marshall, David Heimbrook, Steven M. Stirdivant, А. В. Локтєв, Lopes, Robert Z. Maigetter, Allen Oliff	1992	7
19	Biological activity of a transforming growth factor-alpha-Pseudomonas exotoxin fusion protein in vitro and in vivo Journal of Industrial Microbiology & Biotechnology ·David Heimbrook, Steven M. Stirdivant, А. В. Локтєв, Hans Anton Salomonsen, Denis R. Patrick, Gwynneth M. Edwards, Deborah Defeo-Jones, David Fitzgerald, Ira Pastan, Allen Oliff	1991	2
20	Gastrin releasing peptide antagonists with improved potency and stability Journal of Medicinal Chemistry ·David Heimbrook, Walfred S. Saari, Hans Anton Salomonsen, Antonio Rech, Arthur Friedman, DAVID M. KIEFER, Manoucher Rahmati‐Kamel, 王元英, Allen Oliff	1991	27

About David Heimbrook

David Heimbrook is a scholar working on Oncology, Biophysics, Molecular Biology, Biotechnology and Ophthalmology, having authored 69 papers that have together received 4.6k indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (19 papers), Virus-based gene therapy research (11 papers), Ubiquitin and proteasome pathways (8 papers), Cervical Cancer and HPV Research (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), Melanoma and MAPK Pathways (7 papers), Microtubule and mitosis dynamics (6 papers) and Toxin Mechanisms and Immunotoxins (6 papers). The work is most often cited by research in Oncology (2.3k citations), Molecular Biology (3.0k citations), Cell Biology (609 citations), Biotechnology (295 citations) and Cancer Research (472 citations). David Heimbrook has collaborated with scholars based in United States, Switzerland and Canada. Frequent co-authors include Christian Tovar, Lyubomir T. Vassilev, Allen Oliff, Kathryn Packman, Xiaolan Zhao, Kenneth Kolinsky, Stephen G. Sligar, Brian Higgins, Binh Thanh Vu and Dejan Knezevic. Their work appears in journals such as Journal of Biological Chemistry, Molecular and Cellular Biology, Cancer Research, Proceedings of the National Academy of Sciences and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact